Drug intelligence / Profile preview

Debio 1036

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral

Overview

Debio 1036 is an orally available small molecule developed by Debiopharm International SA under an exclusive license from Yale University for autoimmune and inflammatory diseases. It acts as a first-in-class inhibitor antagonizing macrophage migration inhibitory factor (MIF), a key mediator in the inflammation process central to numerous inflammatory pathologies.[1][7][11][15]

Targets

MIF (Oxidized macrophage migration inhibitory factor)

Beyond the preview

Go deeper on Debio 1036.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 1036.

Explore the full profile